Patents by Inventor David A. Goukassian

David A. Goukassian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF RADIATION EXPOSURE
    Publication number: 20150140009
    Abstract: The invention provides methods for the treatment of radiation exposure featuring agents that interfere with the expression, production, release, accumulation, or activity of a TNF?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES receptor; or a TNF-?, IL6, EGF, IL1-alpha, IL1-beta, G-CSF, MCP-1, MIP-1, SCF, or RANTES peptide or fragment thereof.
    Type: Application
    Filed: August 19, 2014
    Publication date: May 21, 2015
    Inventor: David A. Goukassian
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF A NEOPLASIA
    Publication number: 20130195896
    Abstract: The invention provides methods for the treatments of neoplasia featuring agents that interfere with the expression or activity of a TNFa receptor.
    Type: Application
    Filed: April 7, 2011
    Publication date: August 1, 2013
    Applicant: STEWARD RESEARCH AND SPECIALTY PROJECTS CORPORATION
    Inventor: David A. Goukassian
  • USE OF TUMOR NECROSIS FACTOR-alpha RECEPTOR p75 FOR TREATMENT OF ISCHEMIA-INDUCED NEOVASCULARIZATION
    Publication number: 20120014879
    Abstract: Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients.
    Type: Application
    Filed: October 24, 2006
    Publication date: January 19, 2012
    Applicant: CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON INC
    Inventors: Douglas W. Losordo, David A. Goukassian
  • Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation
    Publication number: 20100150841
    Abstract: As described below, the present invention features compositions and methods for increasing TNFR2/p75 receptor signaling to reduce inflammation. Methods for increasing TNFR2/p75 expression or signaling may also be used to increase the survival of resident cells or transplanted stem cells (e.g., bone marrow derived or peripheral blood derived stem cells) in a damaged tissue.
    Type: Application
    Filed: October 31, 2007
    Publication date: June 17, 2010
    Applicant: CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON, IN
    Inventors: David A. Goukassian, Raj Kishore